These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18029945)

  • 1. Comparisons of aprepitant and ondansetron.
    Carides A; Reiss T; Lines C; McKeon B; Diemunsch P
    Am J Health Syst Pharm; 2007 Dec; 64(23):2422-4; author reply 2424-6. PubMed ID: 18029945
    [No Abstract]   [Full Text] [Related]  

  • 2. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.
    Diemunsch P; Gan TJ; Philip BK; Girao MJ; Eberhart L; Irwin MG; Pueyo J; Chelly JE; Carides AD; Reiss T; Evans JK; Lawson FC;
    Br J Anaesth; 2007 Aug; 99(2):202-11. PubMed ID: 17540667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study flaw in comparisons of aprepitant and ondansetron.
    Cavaretta M; Noviasky J
    Am J Health Syst Pharm; 2007 Feb; 64(4):350. PubMed ID: 17299172
    [No Abstract]   [Full Text] [Related]  

  • 4. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery.
    Vallejo MC; Phelps AL; Ibinson JW; Barnes LR; Milord PJ; Romeo RC; Williams BA; Sah N
    Plast Reconstr Surg; 2012 Feb; 129(2):519-526. PubMed ID: 21987042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant for antiemesis after laparoscopic gynaecological surgery: A randomised controlled trial.
    Ham SY; Shim YH; Kim EH; Son MJ; Park WS; Lee JS
    Eur J Anaesthesiol; 2016 Feb; 33(2):90-5. PubMed ID: 26694939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
    Stiff PJ; Fox-Geiman MP; Kiley K; Rychlik K; Parthasarathy M; Fletcher-Gonzalez D; Porter N; Go A; Smith SE; Rodriguez TE
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):49-55.e1. PubMed ID: 22863840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
    Ades S; Halyard M; Wilson K; Ashikaga T; Heimann R; Kumar S; Blackstock W
    Support Care Cancer; 2017 May; 25(5):1503-1510. PubMed ID: 28032216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis.
    Liu M; Zhang H; Du BX; Xu FY; Zou Z; Sui B; Shi XY
    Medicine (Baltimore); 2015 May; 94(19):e762. PubMed ID: 25984662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiemesis after total joint arthroplasty: does a single preoperative dose of aprepitant reduce nausea and vomiting?
    DiIorio TM; Sharkey PF; Hewitt AM; Parvizi J
    Clin Orthop Relat Res; 2010 Sep; 468(9):2405-9. PubMed ID: 20419358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant.
    Diemunsch P; Apfel C; Gan TJ; Candiotti K; Philip BK; Chelly J; Carides AD; Evans JK; Ho TW; Reiss T
    Curr Med Res Opin; 2007 Oct; 23(10):2559-65. PubMed ID: 17845742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron versus droperidol for postoperative nausea and vomiting.
    Phillips J
    Anesth Analg; 1999 Feb; 88(2):465-6. PubMed ID: 9972777
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.
    Hesketh PJ; Grunberg SM; Herrstedt J; de Wit R; Gralla RJ; Carides AD; Taylor A; Evans JK; Horgan KJ
    Support Care Cancer; 2006 Apr; 14(4):354-60. PubMed ID: 16450086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
    Gan TJ; Apfel CC; Kovac A; Philip BK; Singla N; Minkowitz H; Habib AS; Knighton J; Carides AD; Zhang H; Horgan KJ; Evans JK; Lawson FC;
    Anesth Analg; 2007 May; 104(5):1082-9, tables of contents. PubMed ID: 17456656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
    Rapoport BL
    Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
    Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
    Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
    Bodge M; Shillingburg A; Paul S; Biondo L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1111-3. PubMed ID: 24357337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
    Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
    Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.